Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO
Efficacy and Safety of Neo-Radiochemotherapy Followed Surgery Compared With Definitive Radiochemotherapy in Patients With Initial Unresectable Esophageal Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
A PHASE2 clinical study on Unresectable Esophageal Cancer, this trial is ongoing. The trial is conducted by Tianjin Medical University Cancer Institute and Hospital and has accumulated 6 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Nov 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2022 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .